Datum Orthobiologics

Company Overview

Snapshot

Founded in May 2014 by Itay Itzhaky, Datum Orthobiologics operates with 1–10 employees. The company ceased operations in February 2019, having focused on developing advanced biomaterials for orthopedic ossification and tissue regeneration.

Business overview

Datum Orthobiologics is a Health Tech & Life Sciences company focused on developing innovative orthopedic ossification, bone formation, and tissue regeneration solutions. The company specializes in advanced biomaterials designed to improve the long-term healing and regeneration of musculoskeletal components, particularly for spinal fusion and fracture grafts in trauma medicine. Its core product, GLYMATRIX, has been utilized in dental and aesthetic procedures, with Datum Orthobiologics concentrating its initial efforts on bone graft products.

Strategic signal

In June 2018, Datum Orthobiologics announced its strategy to apply its established dental technology to the orthopedic market. This move signaled a strategic pivot to leverage existing biomaterial expertise, specifically the GLYMATRIX-based products, for broader applications in musculoskeletal healing and regeneration, indicating a potential for market expansion and diversification of its product use cases.

Company Intelligence Q&A

What is Datum Orthobiologics' primary focus?

Datum Orthobiologics focuses on providing innovative orthopedic ossification, bone formation, and tissue regeneration solutions, developing advanced biomaterials for musculoskeletal healing.

When was Datum Orthobiologics founded?

Datum Orthobiologics was founded in May 2014.

What is the core technology developed by Datum Orthobiologics?

The company develops products featuring its patented GLYMATRIX technology, which has been used in dental and aesthetic procedures and is being applied to orthopedic bone graft products.

What was a significant strategic development for Datum Orthobiologics in 2018?

In June 2018, Datum Orthobiologics announced its intention to apply its dental technology to the orthopedic market, aiming to leverage its GLYMATRIX-based products for spinal fusion and fracture grafts.

What is the current operational status of Datum Orthobiologics?

Datum Orthobiologics ceased to operate in February 2019.